TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18836213

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5993

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5993
Study: 16037734

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine with epinephrine 1:200,000
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline 0.9% (placebo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 11923795

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1586

Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 1586
Study: 10384989

Group type: EXPERIMENTAL
Intervention: Psoriatic arthritis patients with radiographic evidence of sacroiliitis (grade 2 or higher)
Number of subjects: 202
Study: 8653819

Group type: EXPERIMENTAL
Intervention: Live, cold-adapted influenza vaccine
Number of subjects: 130000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130000
Study: 1319385

Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 6323087

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg intravenous injection)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg oral dosing)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (intravenous injection)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (oral dosing)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (0.5 microgram/ml serum concentration)
Number of subjects: 10
Study: 30604091

Group type: EXPERIMENTAL
Intervention: Lilly insulin glargine (LY IGlar)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: LY IGlar
Number of subjects: 493
Study: 28556598

Group type: EXPERIMENTAL
Intervention: Epelsiban 300 mg twice daily for 1 day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Epelsiban 200 mg 3 times daily for 14 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Epelsiban 300 mg 3 times daily for 14 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Epelsiban 450 mg twice daily for 14 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Epelsiban 600 mg and 900 mg total daily doses
Number of subjects: 43
Study: 26505571

Group type: EXPERIMENTAL
Intervention: Noncompressible warming mattress (Baby/Kleinkinddecke of MoeckWarmingSystems, Moeck und Moeck GmbH; group MM) at 40°C
Number of subjects: 80

Group type: COMPARATOR
Intervention: Compressible warming mattress system (Pediatric Underbody, Bair Hugger, 3M; group BH) at 43°C
Number of subjects: 80

Group type: COMPARATOR
Intervention: Compressible warming mattress system (group BH)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Noncompressible warming mattress (group MM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 80
Study: 23768191

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Sham electro-acupuncture
Number of subjects: 1034
Study: 21490024

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (OOXY)
Number of subjects: 110
Study: 19763803

Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16766975

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (VAC) for hematomas
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pressure dressing for hematomas (group A)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (VAC) for fractures
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard postoperative dressing for fractures (group A)
Number of subjects: 88
Study: 15636140

Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study: 11134474

Group type: EXPERIMENTAL
Intervention: Adderall (0.15 mg/kg/dose and 0.3 mg/kg/dose)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 9211209

Group type: EXPERIMENTAL
Intervention: Intervention community worksites with no smoke-free policy at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention community worksites with no cessation assistance at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worksites employing 100 to 249 workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worksites predominantly employing men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worksites offering other types of health-promotion activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worksites with a higher rate of turnover
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manufacturing businesses
Number of subjects: 0
Study: 8394815

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg once daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 70
Study: 3333985

Group type: EXPERIMENTAL
Intervention: Conservative functional treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 80
Study: 29989055

Group type: EXPERIMENTAL
Intervention: Gentle assisted pushing (GAP)
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Routine practice (recumbent posture)
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: GAP and Upright position
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Routine practice
Number of subjects: 1158
Study: 26602318

Group type: EXPERIMENTAL
Intervention: Blueberry treatment (300g of blueberries) + smoking (one cigarette)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control treatment (300ml of water with sugar) + smoking (one cigarette)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Smoking treatment (one cigarette)
Number of subjects: 14
Study: 24517142

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (0.01, 0.03, 0.10, 0.30, or 1.00 nmol/kg/h)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 5
Study: 23766644

Group type: EXPERIMENTAL
Intervention: Daily health status measurements during outpatient treatment or admission to hospital.
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: CCQ symptom score (Clinical COPD Questionnaire).
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Health status and gender.
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Age, forced expiratory flow in one second % predicted, smoking status, and CCQ score.
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Health status measurements in outpatient management.
Number of subjects: 255
Study: 20542854

Group type: EXPERIMENTAL
Intervention: Telephone administration of outcome measures
Number of subjects: 19

Group type: COMPARATOR
Intervention: Face-to-face administration of outcome measures
Number of subjects: 19
Study: 18447217

Group type: EXPERIMENTAL
Intervention: Acupuncture at Hegu (LI 4) and Taichong (LR 3) with Qinglong Baiwei method
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Routine acupuncture with Sanyinjiao (SP 6) and Ciliao (BL 32)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Oral administration of Yueyueshu Decoction
Number of subjects: 180
Study: 19436938

Group type: EXPERIMENTAL
Intervention: Sarcopenic Obese (SO)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Sarcopenic (SS)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Normal Lean (NL)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Obese (OO)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Low Appendicular Skeletal Muscle Mass (ASM)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Higher ASM
Number of subjects: 183
Study: 15805349

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at 67 microg/kg per day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at 33 microg/kg per day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Higher-dose regimen (> or =50 microg/kg per day) followed by tapering to approximately 33 microg/kg per day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 28
Study: 12412977

Group type: EXPERIMENTAL
Intervention: BDP-HFA (beclomethasone dipropionate aerosol spray 500 microg b.i.d. via Jet spacer)
Number of subjects: 154

Group type: COMPARATOR
Intervention: CFC (beclomethasone dipropionate aerosol spray 500 microg b.i.d. via Jet spacer)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: BDP-HFA
Number of subjects: 154

Group type: COMPARATOR
Intervention: CFC
Number of subjects: 154
Study: 9494308

Group type: EXPERIMENTAL
Intervention: Postoperative anxiety measured by State Anxiety Inventory Scale on postoperative day 2 and day 3.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective pain measured by McGill Pain Questionnaire Subscales on postoperative day 2.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain intensity and sensory pain measured by McGill Pain Questionnaire Subscales on postoperative day 2 and day 3.
Number of subjects: 0
Study: 8049037

Group type: EXPERIMENTAL
Intervention: Romberg standing test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unterberger treading test
Number of subjects: 20
Study: 3378514

Group type: EXPERIMENTAL
Intervention: Atenolol 50mg twice daily with sustained release nifedipine 20mg twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol 50mg twice daily with sustained release nifedipine 40mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Atenolol 50mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 25
Study: 12802138

Group type: EXPERIMENTAL
Intervention: Dynamotion video intervention
Number of subjects: 208
Study: 30157365

Group type: EXPERIMENTAL
Intervention: Ningmitai Capsules (NMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Terazosin hydrochloride tablets
Number of subjects: 40
Study: 26501499

Group type: EXPERIMENTAL
Intervention: Immediate treatment (N = 33)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Delayed treatment (waitlist-control, N = 34)
Number of subjects: 67
Study: 25099298

Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training (VR‐JIT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 37
Study: 22147900

Group type: EXPERIMENTAL
Intervention: Transradial PCI
Number of subjects: 2977

Group type: COMPARATOR
Intervention: Transfemoral PCI
Number of subjects: 2977
Study: 19716278

Group type: EXPERIMENTAL
Intervention: LABA treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 20
Study: 18549841

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study: 16028789

Group type: EXPERIMENTAL
Intervention: Hearing aid use
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no hearing aid)
Number of subjects: 102
Study: 12075846

Group type: EXPERIMENTAL
Intervention: Reports of controlled trials identified from AMI
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Quality of indexing of trials in AMI
Number of subjects: 512
Study: 10619101

Group type: EXPERIMENTAL
Intervention: Artificially loaded healthy subjects carrying load in the hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal subjects carrying load on the ankles
Number of subjects: 0
Study: 7669477

Group type: EXPERIMENTAL
Intervention: 2% lignocaine 3.5 ml
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine 3 ml
Number of subjects: 30
Study: 2257867

Group type: EXPERIMENTAL
Intervention: SCR 4 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SCR 8 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: SCR 4 mg and SCR 8 mg
Number of subjects: 15
Study: 36117

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 2-2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 31092044

Group type: EXPERIMENTAL
Intervention: mHealth mindfulness intervention for 8 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care (wait-list control group)
Number of subjects: 128
Study: 29443538

Group type: EXPERIMENTAL
Intervention: Arthroscopic hip surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physical therapy (12-session supervised clinic program)
Number of subjects: 80
Study: 26920590

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) - sirolimus-eluting stents (SES) and everolimus-eluting stents (EES)
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2314

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 2314
Study: 25066876

Group type: EXPERIMENTAL
Intervention: 1-day mifepristone-misoprostol interval
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: 2-day mifepristone-misoprostol interval
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (same-day reports)
Number of subjects: 217
Study: 22913680

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (banding 19%, vertical banded gastroplasty 69%, gastric bypass 12%)
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1658
Study: 20477774

Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average drinks per drinking day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency of drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total drinks per month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictors of drinking changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other factors predicting drinking change
Number of subjects: 0
Study: 17716499

Group type: EXPERIMENTAL
Intervention: Congenital heart disease (35%)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Renal hypertensive disease (26%)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Rheumatic heart disease (17%)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cardiomyopathies (12%)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Endomyocardial fibrosis (7%)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tamponade (3%)
Number of subjects: 58
Study: 16376250

Group type: EXPERIMENTAL
Intervention: Tibial cement used in total knee arthroplasty (30 knees)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No tibial cement used in total knee arthroplasty (30 knees)
Number of subjects: 57
Study: 12075703

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy to the chest after resection for Stage II and IIIA NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy for Stage IIIA NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study: 11390029

Group type: EXPERIMENTAL
Intervention: N-acetylcarnosine, 1% sol (NAC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (placebo and untreated)
Number of subjects: 49
Study: 9581951

Group type: EXPERIMENTAL
Intervention: Reverse polarity (RV apex = anode)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal polarity (RV apex = cathode)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reverse polarity (RV apex = anode) in patients with high DFT (> or = 15 J)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal polarity (RV apex = cathode) in patients with high DFT (> or = 15 J)
Number of subjects: 60
Study: 7924900

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (EPO, Epogam, Searle, U.K.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (high dose EPO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (EPO)
Number of subjects: 0
Study: 3287911

Group type: COMPARATOR
Intervention: Piroxicam 40 mg once daily for two days, then 20 mg daily for five days
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for five days
Number of subjects: 74
Study: 4616802

Group type: EXPERIMENTAL
Intervention: Duphalac (lactulose preparation)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Irritant laxatives (containing senna, anthraquinone derivatives, or bisacodyl)
Number of subjects: 164
Study: 31565796

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) 2 days/week at the clinic with adherence support
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CG) with two AIT sessions and encouraged to exercise on their own
Number of subjects: 48
Study: 28600159

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet) alone, without weight loss
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet lifestyle intervention to promote weight loss and weight loss maintenance
Number of subjects: 180

Group type: COMPARATOR
Intervention: Typical Diet Control
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both MedDiet intervention groups
Number of subjects: 180
Study: 26153197

Group type: EXPERIMENTAL
Intervention: Symbiotic tablet (1 tablet daily for 8 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo tablet (1 tablet daily for 8 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Symbiotic tablet
Number of subjects: 44
Study: 23332327

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (15-month intervention targeting organizational and environmental changes)
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Delayed control group (no intervention during the 15-month period)
Number of subjects: 1257
Study: 21839689

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Education (EDU)
Number of subjects: 52
Study: 19179316

Group type: EXPERIMENTAL
Intervention: Intensive 6-month weight-loss program (diet, exercise, behavior modification)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Structured education program
Number of subjects: 338
Study: 17002709

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 mcg once daily for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15284344

Group type: EXPERIMENTAL
Intervention: l‐NAME (4 mg kg(‐1) in 50 ml saline)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (50 ml saline)
Number of subjects: 7
Study: 11712229

Group type: EXPERIMENTAL
Intervention: Hyperoxia (inspiratory concentration of oxygen raised from 0.4 to 1.0 for 15 minutes)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normoxia (control group, FiO2 0.4)
Number of subjects: 22
Study: 9113184

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 0.625 microgram/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 1.25 micrograms/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 8227488

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 58
Study: 2868812

Group type: EXPERIMENTAL
Intervention: Intracoronary propranolol (1.1 +/- 0.2 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intracoronary placebo (saline, 2 ml)
Number of subjects: 21
Study: 30198863

Group type: EXPERIMENTAL
Intervention: Five up-regulated miRNAs (miR-200a-3p, miR-296-5p, miR-132-3p, miR-485-3p, and miR-22-5p) identified in serum of GCA patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GCA tissues
Number of subjects: 102

Group type: COMPARATOR
Intervention: Exosomes
Number of subjects: 102
Study: 26551659

Group type: EXPERIMENTAL
Intervention: Couple intervention (Marriage Checkup - MC)
Number of subjects: 244
Study: 24290209

Group type: EXPERIMENTAL
Intervention: 20 min of mild‐to‐moderate intensity exercise (EC; n=14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive condition (PC; n=16)
Number of subjects: 30
Study: 23053458

Group type: EXPERIMENTAL
Intervention: Non-absorbable polypropylene mesh (Optilene® Mesh Elastic)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Partly absorbable mesh (Ultrapro® Mesh)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 19711335

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 17652214

Group type: EXPERIMENTAL
Intervention: LIPID (intralipid infusion at 20% at 90 ml/h plus heparin 200 U prime + 600 U/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON (without intralipid infusion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LIPID
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LIPID and CON
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON
Number of subjects: 10
Study: 16324159

Group type: EXPERIMENTAL
Intervention: Migraine diagnosis (IHS categories 1.1 and 1.2)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Other forms of episodic headache
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Headache-free status
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Frequency and severity of headaches
Number of subjects: 2500
Study: 14504812

Group type: EXPERIMENTAL
Intervention: Itraconazole solution
Number of subjects: 106

Group type: COMPARATOR
Intervention: Amphotericin B solution
Number of subjects: 106
Study: 10357538

Group type: EXPERIMENTAL
Intervention: Spinal accessory nerve transfer
Number of subjects: 205

Group type: COMPARATOR
Intervention: Intercostal nerve transfer
Number of subjects: 205
Study: 8602564

Group type: EXPERIMENTAL
Intervention: Verapamil retard 360 mg/day
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073